IL15 and cancer: To address the safety challenges and enhance the therapeutic potential of IL-15-based cancer therapies, the present study leverages the inherent tumor tropism of E. coli Nissle 1917 (EcN), a probiotic bacterium, and engineers EcN to display the protease-sensitive cytokine IL-15 on its outer membrane using the bacterial display vector pNeae2.34